Photo from Paolo Tarantino/X
Jan 29, 2024, 10:53
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard University, shared a post on X/Twitter:
“The highly debated results of PALOMA2 now published on JCO: the addition of palbociclib to 1L letrozole did not improve OS in HR+ MBC. The reason for the discrepancy with ribociclib and abemaciclib data remains unclear. Ultimately led to a reduction in the use of palbociclib.”
View additional information.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14